Trending stocks today
Fulgent Genetics (FLGT-Q)
NASDAQ:FLGT
20.13
0.10
(0.49%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
The reviews from different experts suggest that while Fulgent Genetics has the potential for growth, it may face challenges in the near future. Despite declining revenue, the most recent earnings beat estimates, and the company's pharma side shows promise with patents and a lead drug candidate. The balance sheet remains strong, but there are concerns about the future. Overall, the outlook is cautious with acknowledgment of both positive and negative aspects of the company.
$21.480
Unknown
- «
- ‹
- 1
- ›
- »
Fulgent Genetics(FLGT-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 1
Fulgent Genetics(FLGT-Q) Frequently Asked Questions
What is Fulgent Genetics stock symbol?
Fulgent Genetics is a American stock, trading under the symbol FLGT-Q on the NASDAQ (FLGT). It is usually referred to as NASDAQ:FLGT or FLGT-Q
Is Fulgent Genetics a buy or a sell?
In the last year, 1 stock analyst published opinions about FLGT-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Fulgent Genetics.
Is Fulgent Genetics a good investment or a top pick?
Fulgent Genetics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Fulgent Genetics.
Why is Fulgent Genetics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Fulgent Genetics worth watching?
1 stock analyst on Stockchase covered Fulgent Genetics In the last year. It is a trending stock that is worth watching.
What is Fulgent Genetics stock price?
On 2024-12-11, Fulgent Genetics (FLGT-Q) stock closed at a price of $20.13.
We have some comments posted on FLGT. While it is not without potential, it is likely going to get worse before it bets better, growth-wise. The most recent quarterly earnings were fine as revenue continued to decline, but beat estimates, along with EPS. There are positives as the pharma side of the business is making progress with over 30 issued or active patents and a promising lead drug candidate. The balance sheet does continue to be strong. We are OK selling.
Unlock Premium - Try 5i Free